BioNTech SE (BNTX) Actualités

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025

MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

BioNTech Completes Acquisition of Biotheus

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities